- The ILLUMENATE & ILLUMENATE EU RCT studies results involve assessing of Stellarex .035 DCB vs uncoated balloons in patients with the peripheral arterial disease for 3yrs.
- The ILLUMENATE & ILLUMENATE EU RCT studies results: @36mos. maintenance of blood flow through diseased arteries (64.2% & 67.5% vs 51.0% & 59.9%); mortality rate (10.1% & 9.4% vs 11.0% vs 8.5%) respectively
- Stellarex .035 is a low-dose drug-coated balloon intended to restore and maintain blood flow in diseased femoral and popliteal arteries featuring EnduraCoat Technology and has received FDA’s approval in the US and CE marking in Europe
Click here to read full press release/ article | Ref: Philips | Image: Spectranetics